Sareum Holdings plc
("Sareum" or the "Company")
Final
Issue of RiverFort Subscription Shares
Cambridge, UK, 23 April 2024 -
Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology
company developing next-generation kinase inhibitors for autoimmune
disease and cancer, announces that it has issued 2,260,488 new
Ordinary Shares in the capital of the Company to RiverFort Global
Opportunities PCC Ltd (the "Riverfort Shares"), in accordance with the terms
of the Facility announced on 3 August 2023 (the "Riverfort Facility").
The issuance of the Riverfort Shares
will settle the full outstanding balance on the Riverfort Facility.
As noted in Sareum's announcement of 28 March 2024, the Company
does not intend to make any further withdrawals pursuant to the
Riverfort Facility and accordingly the Company will not be issuing
any further Subscription Shares pursuant to the Riverfort
Facility.
Admission and Total Voting Rights
Application has been made to the
London Stock Exchange plc for the admission of 2,260,488 new
Ordinary Shares to trading on AIM ("Admission"). It is expected that
Admission will occur at 8.00 a.m. (London time) on or around Friday
26 April 2024.
Immediately following Admission, the
total number of Ordinary Shares in issue will be 106,838,797 and
the total number of voting rights will therefore be 106,838,797,
and this figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure and
Transparency Rules.
Terms and definitions used in this announcement shall have the
same meaning as ascribed to them in the Company's announcement
dated 3 August 2023, unless otherwise stated.
For Further
Information:
|
Sareum
Holdings plc
Tim Mitchell,
CEO
|
01223 497700
ir@sareum.co.uk
|
|
Strand Hanson
Limited (Nominated Adviser)
James Dance / James Bellman
|
020 7409
3494
|
|
Peel Hunt LLP
(Joint Corporate Broker)
|
020 7418
8900
|
|
James Steel / Patrick Birkholm
|
|
|
Hybridan LLP (Joint
Corporate Broker)
Claire Noyce
|
020 3764
2341
|
|
ICR Consilium
(Financial PR)
Jessica Hodgson / Davide Salvi / Kumail Waljee
|
0203 709
5700
|
About
Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage
biotechnology company developing next generation kinase inhibitors
for autoimmune disease and cancer.
The Company is focused on developing next
generation small molecules which modify the activity of the JAK
kinase family and have best-in-class potential. Its lead candidate,
SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a
potential treatment for a range of autoimmune diseases and has
entered Phase 1a/b clinical development with an initial focus on
psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1
inhibitor with a potential application for cancer
immunotherapy.
Sareum Holdings plc is based in Cambridge, UK,
and is listed on the AIM market of the London Stock Exchange,
trading under the ticker SAR. For further information, please visit
the Company's website at www.sareum.com